What criteria do venture debt lenders apply?
The syndicate first, the company second. A venture lender's core questions are about the investors on the register: who led the most recent round, how recently it priced, how much capital those funds have in reserve, where they are in their own fund cycles, and whether their behaviour suggests they would support the company again. The underwriting rests on the proposition that the syndicate, not the company's current earnings, is the source of repayment.
Then the company's own file, read through that lens: burn rate and runway under the board plan and under a slower one; the enterprise value implied by the last round against the debt proposed; the credibility of the milestones the extended runway is supposed to reach; and cohort-level operating data showing the plan is trajectory rather than hope. The evidence set is the cap table, the round documents, the board-approved plan, and the operating metrics behind it.
What is conspicuously absent from the list is profitability. Venture debt is one of the few credit products that does not ask for it, which is precisely why the substitute criteria are so specific: the lender who waives the earnings test needs the syndicate test to be strong, and a weak answer on the investors is rarely offset by a strong answer on anything else.
What terms should a qualifying company expect?
Sized off the round, not the revenue. Convention ties facility size to the most recent equity raise, typically 20 to 35 percent of it, at rates often in the 8 to 12 percent range, over terms of 24 to 48 months with an initial interest-only period before principal repayments begin (Kruze Consulting venture debt guide, accessed 7 September 2026). A company that raised $10m can usually talk about $2m to $3.5m of debt; a company that raised nothing institutional has no base for the sizing convention to work from, which previews the next section.
The warrant is the term that deserves the most negotiation and gets the least. Lenders take warrants, rights to buy equity at a set price, alongside the loan; the dilution is usually under 1 percent of the cap table (same source), which sounds trivial and is exactly why it is under-negotiated. Warrants cost nothing in the failure case and real money in the success case, so their coverage, strike, and treatment on an acquisition are terms about the outcome everyone is working toward, and the dispersion between lenders on warrant terms is wider than on rates.
The covenants that matter are the ones referencing investor behaviour. Material-adverse-change and investor-abandonment language decides what happens if the syndicate's support wavers, which is the moment the facility is most needed, and it is the real risk allocation in the document. A borrower comparing term sheets on rate and warrant alone has not yet read the part of the document the lender drafted most carefully.
“Founders bring us term sheets ranked by interest rate. Re-ranked by the investor-abandonment clause and the warrant treatment on a sale, the order usually reverses.”
Does a company without venture backing qualify?
Not with venture lenders as the product is conventionally practised, and it is worth being precise about why: the underwriting described above needs an institutional syndicate to underwrite. Remove the syndicate and the venture lender has no repayment thesis, so most will decline regardless of how the company itself is performing.
That is a boundary of one lender class, not of debt. Growth-focused non-bank lenders underwrite the company directly, on revenue quality, retention, margins and traction, without requiring a sponsor on the register: this is the territory of revenue-based financing and ARR lending, and for a bootstrapped or lightly backed growth company it is the door that actually opens. The comparison piece linked below sets the two products side by side at constant capital need.
The practical cost of misreading the boundary is time. A founder without institutional backing who spends a quarter pitching venture lenders collects polite declines that say nothing about the company's fundability, while a venture-backed founder pitching revenue-based lenders is usually paying for flexibility the syndicate already gives them. Knowing which register the company is on before approaching anyone is the cheapest piece of capital-markets advice there is.
| Venture lender | Revenue-based or ARR lender | |
|---|---|---|
| What is underwritten | The investor syndicate | The company's own revenue and retention |
| Sizing basis | The last equity round | Recurring revenue or collections |
| Institutional backing | Effectively required | Not required |
| Earnings test | Waived; syndicate test instead | Waived; revenue-quality test instead |
| Equity given up | Warrants, negotiated | Usually none |
| Built for | Bridging to the next priced round | Growth capital without a sponsor |
When does a qualifying company raise it, and for what?
At or near an equity round, from strength. Terms are strongest when the syndicate's commitment is freshest and the lender's central question answers itself; raising venture debt long after the round, out of visible need, meets a different market at different terms. The window is a criterion in its own right, and companies that qualify in January can find themselves un-qualifying by October without anything changing except the calendar (market convention).
The use case the product is built for is a bridge between priced events: extending runway to a milestone the next round will price, a product release, a revenue threshold, a regulatory step, without selling equity at today's valuation to get there. Debt drawn toward a milestone arrives at the next round as evidence of discipline. The same debt drawn to fund a missed plan arrives as an obligation senior to every shareholder, at the moment the equity story is weakest.
Which is the last criterion, and the one the company applies to itself: whether the facility is funding a milestone or a delay. Lenders price the first and eventually own the second, and the difference is visible in the board plan long before it is visible in the covenant compliance certificate.
As of September 2026
Sources: Kruze Consulting venture debt guide, kruzeconsulting.com, accessed 7 September 2026 (facility sizing typically 20 to 35 percent of the most recent equity round; rates often 8 to 12 percent; terms of 24 to 48 months with an initial interest-only period; warrant dilution usually under 1 percent of the cap table). The underwriting criteria, covenant mechanics and timing dynamics described are market convention, stated figure-free. The revenue-based financing comparison carries its own sources in the linked position and none of its pricing is restated here.
This position sits within our venture debt practice.